查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870013

美國肉牛健康市場規模、佔有率和趨勢分析報告：按產品、分銷管道和細分市場預測（2025-2033 年）

U.S. Beef Cattle Health Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Medicated Feed Additives), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國肉牛健康市場摘要

據估計，美國肉牛健康管理市場在 2024 年的價值為 11.2 億美元，預計到 2033 年將達到 23.5 億美元。

預計2025年至2033年，該市場將以8.80%的複合年成長率成長。推動市場成長的因素包括感染疾病和寄生蟲病的日益流行、畜群規模縮小導致人們對動物健康和生產力的日益關注，以及對預防性獸醫保健投入的增加。此外，牛價上漲和生物安全問題也加速了育肥場對疫苗、診斷和健康監測技術的應用。

牛中地方性疾病和新興疾病的日益普及是美國肉牛健康產業的主要成長要素，帶動了對診斷、疫苗、治療和預防策略的需求。例如，根據美國農業部 (USDA) 的報告，牛呼吸道疾病 (BRD) 仍然是育肥牛面臨的最昂貴的健康問題之一。研究表明，降低 BRD 的死亡率和發病率可以改善動物福利，影響牛肉供應，降低成本，並對下游市場（包括牛、飼料和牛肉價格）產生影響。

另一個例子是新世界螺旋蠅的再次出現，這導致了進口禁令（例如來自墨西哥的禁令）、治療和生物安全成本的增加，並因推高牛肉價格而威脅到供應。為了應對這個問題，畜牧生產者正在增加對動物健康基礎設施的投資，包括加強監測、快速診斷、研發新型疫苗和抗寄生蟲藥物，以及改善畜群管理措施。這些投資正在擴大畜牧保健市場。根據美國農業部（USDA）預測，到2024年，美國將佔據北美牛保健市場約87%的佔有率。預防醫學、診斷技術、精準畜牧業和治療藥物都是美國市場中成長快速的領域。這些趨勢表明，生產者和政策制定者都認知到，疾病預防對於保護牲畜、穩定市場、保障出口以及維持牛肉價格的合理性至關重要。

此外，美國食品藥物管理局(FDA)核准的牛用藥數量不斷增加，也推動了美國肉牛健康市場的發展，擴大了生產者可選擇的預防和治療方案範圍。近期核准，例如用於預防螺旋蠅的 Dectomax CA1 和用於治療牛呼吸道疾病的 Pradarex，為牧場主提供了保護牛群健康、降低死亡率和提高生產力的實用工具。這些核准的核准促進了生物製藥、藥品和藥用飼料的應用，使生產者能夠更有效地管理疾病並減少經濟損失，從而支持整體市場成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 市場變數的趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 定價分析
  • 2024年動物數量估計
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析與SWOT分析

第4章：美國肉牛健康市場：依產品分類的估算與趨勢分析

  • 美國肉牛健康市場按產品分類：細分儀表板
  • 美國肉牛健康市場產品波動分析
  • 按產品分類，2021-2033 年
  • 生物製藥
  • 製藥
  • 藥品和飼料添加劑

第5章：美國肉牛健康市場：按分銷管道分類的估算與趨勢分析

  • 美國肉牛健康市場按分銷管道分類：細分儀表板
  • 美國肉牛健康市場：按分銷管道分析波動情況
  • 按分銷管道分類，2021-2033 年
  • 醫院/診所藥房
  • 零售
  • 電子商務

第6章 競爭情勢

  • 市場參與企業分類
    • 市場領導者
    • 新興參與者
  • 2024年市佔率/評級分析（熱力圖分析）
  • 公司簡介
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Merck &Co., Inc.
    • Virbac
    • Elanco
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Norbrook
    • Dechra Pharmaceuticals Plc
    • Bimeda, Inc
    • Cargill, Incorporated
  • 其他主要企業名單
Product Code: GVR-4-68040-778-0

U.S. Beef Cattle Health Market Summary

The U.S. beef cattle health market size was estimated at USD 1.12 billion in 2024 and is projected to reach USD 2.35 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The market is experiencing growth driven by the rising prevalence of infectious and parasitic diseases, shrinking cattle herds prompting greater focus on animal health and productivity, and increasing investments in preventive veterinary care. Additionally, high cattle values and biosecurity concerns are accelerating the adoption of vaccines, diagnostics, and health monitoring technologies across beef operations.

Rising disease prevalence among cattle, both endemic and emerging, has become a major growth driver for the U.S. beef cattle health industry, pushing increased demand for diagnostics, vaccines, therapeutics, and preventive strategies. For example, as per the USDA report, Bovine Respiratory Disease (BRD) remains one of feedlot cattle's costliest health issues. Several studies show that reductions in mortality and morbidity from BRD improve animal welfare, affect beef supply, lower costs, and influence downstream markets for cattle, feed, and beef prices.

Another example is the re-emergence of the New World Screwworm, which threatens supply by prompting import bans (e.g., from Mexico), increasing treatment and biosecurity costs, and pushing beef prices upward. In response, cattle producers are investing more heavily in animal health infrastructure: enhanced surveillance, rapid diagnostics, new vaccines or antiparasitic drugs, and improved herd management practices. This investment is enlarging the cattle healthcare market. According to the USDA, in 2024, the U.S. accounted for almost 87% of the North American cattle healthcare market. Preventive healthcare, diagnostics, precision livestock farming, and therapeutics are all growing segments in the U.S. market. These trends also signal that producers and policymakers recognize disease prevention as economically essential to safeguard animals and ensure market stability, export access, and beef affordability.

Additionally, the rising number of FDA-approved drugs for beef cattle is driving the U.S. beef cattle health market, as it expands the range of available preventive and therapeutic options for producers. Recent approvals, such as Dectomax-CA1 for New World screwworm prevention and Pradalex for bovine respiratory disease, provide ranchers with practical tools to protect herd health, reduce mortality, and improve productivity. These approvals also encourage the adoption of biologics, pharmaceuticals, and medicated feed additives, enabling producers to manage disease more efficiently and mitigate economic losses, fueling overall market growth.

U.S. Beef Cattle Health Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. beef cattle health market report based on product and distribution channel:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
    • Vaccines
    • Attenuated Live Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • DNA Vaccines
    • Recombinant Vaccines
    • Autogenous Vaccines
    • Other Biologics
  • Pharmaceuticals
    • Parasiticides
    • Anti-infectives
    • Anti-inflammatory
    • Analgesics
    • Others
  • Medicated Feed Additives
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail
  • E-commerce
  • Hospital/Clinic Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information/Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Model 1 Analysis
    • 1.7.2. Model 2 Analysis
    • 1.7.3. Model 3 Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary/Related Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing beef availability for domestic consumption
      • 3.2.1.2. Strong overseas demand for U.S. beef
      • 3.2.1.3. Supportive initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory challenges
      • 3.2.2.2. Adverse environmental conditions
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Pricing Analysis
  • 3.4. Estimated Animal Population, 2024
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Beef Cattle Health Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Beef Cattle Health Market, By Product: Segment Dashboard
  • 4.2. U.S. Beef Cattle Health Market, By Product Movement Analysis
  • 4.3. U.S. Beef Cattle Health Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
  • 4.4. Biologics
    • 4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1. Vaccines
        • 4.4.1.1.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.2. Attenuated Live Vaccines
          • 4.4.1.1.2.1. Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.3. Inactivated Vaccines
          • 4.4.1.1.3.1. Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.4. Subunit Vaccines
          • 4.4.1.1.4.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.5. DNA Vaccines
          • 4.4.1.1.5.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.6. Recombinant Vaccines
          • 4.4.1.1.6.1. Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.1.1.7. Autogenous Vaccines
          • 4.4.1.1.7.1. Autogenous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.2. Other Biologics
        • 4.4.1.2.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pharmaceuticals
    • 4.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.1. Parasiticides
        • 4.5.1.1.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.2. Anti-infectives
        • 4.5.1.2.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.3. Anti-inflammatory
        • 4.5.1.3.1. Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.4. Analgesics
        • 4.5.1.4.1. Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.5.1.5. Others
        • 4.5.1.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Medicated Feed Additives
    • 4.6.1. Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Beef Cattle Health Market: By Distribution Channel Estimates & Trend Analysis

  • 5.1. U.S. Beef Cattle Health Market, By Distribution Channel: Segment Dashboard
  • 5.2. U.S. Beef Cattle Health Market, By Distribution Channel Movement Analysis
  • 5.3. U.S. Beef Cattle Health Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital/Clinic Pharmacy
    • 5.4.1. Hospital/Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Retail
    • 5.5.1. Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. E-commerce
    • 5.6.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Market Leaders
    • 6.1.2. Emerging Players
  • 6.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 6.3. Company Profiles
    • 6.3.1. Zoetis Inc.
      • 6.3.1.1. Participant's Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Product/Service Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Boehringer Ingelheim International GmbH
      • 6.3.2.1. Participant's Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Product/Service Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Merck & Co., Inc.
      • 6.3.3.1. Participant's Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Product/Service Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Virbac
      • 6.3.4.1. Participant's Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Product/Service Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Elanco
      • 6.3.5.1. Participant's Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Product/Service Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. Vetoquinol S.A
      • 6.3.6.1. Participant's Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Product/Service Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Phibro Animal Health Corporation
      • 6.3.7.1. Participant's Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Product/Service Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. Norbrook
      • 6.3.8.1. Participant's Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Product/Service Benchmarking
      • 6.3.8.4. Strategic Initiatives
    • 6.3.9. Dechra Pharmaceuticals Plc
      • 6.3.9.1. Participant's Overview
      • 6.3.9.2. Financial Performance
      • 6.3.9.3. Product/Service Benchmarking
      • 6.3.9.4. Strategic Initiatives
    • 6.3.10. Bimeda, Inc
      • 6.3.10.1. Participant's Overview
      • 6.3.10.2. Financial Performance
      • 6.3.10.3. Product/Service Benchmarking
      • 6.3.10.4. Strategic Initiatives
    • 6.3.11. Cargill, Incorporated
      • 6.3.11.1. Participant's Overview
      • 6.3.11.2. Financial Performance
      • 6.3.11.3. Product/Service Benchmarking
      • 6.3.11.4. Strategic Initiatives
  • 6.4. List of other key players

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Beef Cattle Health Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Beef Cattle Health Market Estimates and Forecasts, by Vaccine, 2021 - 2033 (USD Million)
  • Table 5 U.S. Beef Cattle Health Market Estimates and Forecasts, by Pharmaceuticals, 2021 - 2033 (USD Million)
  • Table 6 U.S. Beef Cattle Health Market Estimates and Forecasts, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Commodity Flow Analysis
  • Fig. 7 Value Chain-Based Sizing & Forecasting
  • Fig. 8 QFD Model Sizing & Forecasting
  • Fig. 9 Bottom-Up Approach
  • Fig. 10 Market Snapshot
  • Fig. 11 Segment Snapshot 1
  • Fig. 12 Segment Snapshot 2
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent Market Outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary Market Outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Beef Cattle Health Market Dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL Analysis
  • Fig. 19 U.S. Beef Cattle Health Market: Product Outlook and Key Takeaways
  • Fig. 20 U.S. Beef Cattle Health Market: Product Movement Analysis
  • Fig. 21 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Autogenous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Beef Cattle Health Market: Distribution Channel Outlook and Key Takeaways
  • Fig. 38 U.S. Beef Cattle Health Market: Distribution Channel Movement Analysis
  • Fig. 39 Hospital/Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key company categorization
  • Fig. 43 Product/Service heat map analysis
  • Fig. 44 Strategic framework